A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Jui-Chun ChangYu-Chiao YiYa-Fang ChenHwa-Fen GuuHsiao-Fan KungLi-Yu ChenShih-Ting ChuanYu-Mei ChangMing-Jer ChenPublished in: Archives of gynecology and obstetrics (2023)
The cost analysis showed that recombinant LH is more cost-effective than hMG supplementation on r-hFSH during COH in the GnRH-antagonist protocol.